Xiang M, et al. - Researchers sought the comparative efficacy of cisplatin vs cetuximab in combination with radiation (RT) for the definitive treatment of head and neck cancers. They searched the Surveillance, Epidemiology, and End Results-Medicare database and identified 1395 patients with locoregionally advanced (American Joint Committee on Cancer stage III-IVB) squamous cell carcinomas of the oropharynx, larynx, or hypopharynx. Among these, 786 received cisplatin and 609 received cetuximab. Outcomes suggest significantly higher cancer-specific mortality (CSM) in correlation to treatment with cetuximab vs cisplatin. Hence in this setting, cisplatin may be the preferred chemotherapeutic agent.